Alongside this hypothesis, one would expect similar clinical benefits from other SGLT inhibitors, particularly those less selective for SGLT2. In a meta-analysis of 21 phase 2b-3 studies that involved 9,339 diabetic patients at varying cardiovascular risk treated with empagliflozin, there were also similar but statistically insignificant reductions in cardiovascular death and heart failure-related hospitalizations18. This evidence concerns the gene SLC5A2 and heart failure.